• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从 Barrett 食管发病到有症状的腺癌的最短潜伏期。

The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma.

机构信息

Department of Gastroenterology and Hepatology, Erasmus Medical Centre, Room Ba393, PO Box 2040, 3000 CA Rotterdam, The Netherlands.

出版信息

Br J Cancer. 2011 Jul 12;105(2):200-5. doi: 10.1038/bjc.2011.214. Epub 2011 Jun 14.

DOI:10.1038/bjc.2011.214
PMID:21673678
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3142800/
Abstract

BACKGROUND

The interval between the onset of Barrett's oesophagus (BO) and oesophageal adenocarcinoma (OAC) can be termed the incubation period. However, the unrecorded onset of BO precludes its direct observation.

METHODS

Determining the range of intervals between BO diagnosis and OAC within the longest observational BO follow-up study. Exclusion criteria were presence of high-grade dysplasia (HGD) or OAC at baseline, death within <2 years of BO diagnosis, oesophagectomy without HGD/OAC and loss to follow-up. A total of 133 patients (M/F 73/60) were taken into account.

RESULTS

In 1967 person years of follow-up there were 13 cases of HGD/OAC, (0.66% p.a.; 95% CI 0.58-0.74), 96 patients died without HGD/OAC and 24 survived without HGD/OAC. The mean intervals between BO diagnosis and either HGD/OAC, death or end of follow-up were 10.8, 12.6 and 25.5 years, respectively, and the mean ages at endpoint were 72.5, 80.0 and 68.3 years, respectively. The survivors without HGD/OAC had a lower age at BO diagnosis (mean 42.8 vs 61.2 and 67.4 years, P<0.001). Baseline presence of low-grade dysplasia was associated with progression to HGD/OAC (log rank P<0.001).

CONCLUSION

The Rotterdam BO follow-up cohort revealed a long incubation period between onset of BO and development of HGD/OAC, in patients without HGD/OAC at baseline as illustrated by 24 patients diagnosed with BO at a young age and followed for a mean period of 25.5 years. Their tumour-free survival established a minimum incubation period, suggesting a true incubation period of three decades or more.

摘要

背景

巴雷特食管(BO)和食管腺癌(OAC)之间的间隔时间可称为潜伏期。然而,BO 的无记录发病使其无法直接观察。

方法

确定最长 BO 随访研究中 BO 诊断与 OAC 之间的间隔范围。排除标准为基线时存在高级别异型增生(HGD)或 OAC、BO 诊断后 2 年内死亡、无 HGD/OAC 的食管切除术以及失访。共纳入 133 例患者(M/F 73/60)。

结果

在 1967 人年的随访中,有 13 例 HGD/OAC(0.66%p.a.;95%CI0.58-0.74),96 例患者无 HGD/OAC 死亡,24 例无 HGD/OAC 存活。BO 诊断与 HGD/OAC、死亡或随访结束之间的平均间隔分别为 10.8、12.6 和 25.5 年,终点年龄分别为 72.5、80.0 和 68.3 岁。无 HGD/OAC 的幸存者 BO 诊断年龄较低(分别为 42.8、61.2 和 67.4 岁,P<0.001)。基线存在低级别异型增生与进展为 HGD/OAC 相关(对数秩 P<0.001)。

结论

鹿特丹 BO 随访队列显示,在基线时无 HGD/OAC 的患者中,BO 发病与 HGD/OAC 发展之间存在较长的潜伏期,如图中 24 例 BO 诊断年龄较小的患者所示,随访时间平均为 25.5 年。他们的无肿瘤生存确立了最短的潜伏期,提示潜伏期真实存在三十年或更长时间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/3142800/c10aafb80bca/bjc2011214f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/3142800/5174ada40062/bjc2011214f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/3142800/4c5f5a66f174/bjc2011214f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/3142800/c10aafb80bca/bjc2011214f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/3142800/5174ada40062/bjc2011214f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/3142800/4c5f5a66f174/bjc2011214f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/3142800/c10aafb80bca/bjc2011214f3.jpg

相似文献

1
The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma.从 Barrett 食管发病到有症状的腺癌的最短潜伏期。
Br J Cancer. 2011 Jul 12;105(2):200-5. doi: 10.1038/bjc.2011.214. Epub 2011 Jun 14.
2
Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.长段 Barrett 食管患者的监测:成本效益分析。
Gut. 2015 Jun;64(6):864-71. doi: 10.1136/gutjnl-2014-307197. Epub 2014 Jul 18.
3
Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus.巴雷特食管患者发生食管腺癌的风险。
Eur J Cancer. 2017 Apr;75:41-46. doi: 10.1016/j.ejca.2016.12.037. Epub 2017 Feb 17.
4
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.非甾体抗炎药、他汀类药物、低剂量阿司匹林和质子泵抑制剂与巴雷特食管患者发生食管腺癌的风险:一项基于人群的病例对照研究。
BMJ Open. 2015 Jan 29;5(1):e006640. doi: 10.1136/bmjopen-2014-006640.
5
Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.经专家病理小组进行组织学复查后,低度异型增生的 Barrett 食管患者可被准确地进行危险分层。
Gut. 2015 May;64(5):700-6. doi: 10.1136/gutjnl-2014-307278. Epub 2014 Jul 17.
6
Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.抑酸药物与 Barrett 食管患者食管腺癌风险的关系:系统评价和荟萃分析。
Gut. 2014 Aug;63(8):1229-37. doi: 10.1136/gutjnl-2013-305997. Epub 2013 Nov 12.
7
Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years.平均随访12.7年后长段巴雷特食管患者的食管癌发病率和死亡率
Scand J Gastroenterol. 2004 Dec;39(12):1175-9. doi: 10.1080/00365520410003524.
8
Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.监测 Barrett 食管对肿瘤分期和肿瘤进展患者生存的影响。
Gut. 2016 Apr;65(4):548-54. doi: 10.1136/gutjnl-2014-308802. Epub 2015 Apr 22.
9
The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off.英国和荷兰的 Barrett 食管和食管腺癌的发病率趋于平稳。
Aliment Pharmacol Ther. 2014 Jun;39(11):1321-30. doi: 10.1111/apt.12759. Epub 2014 Apr 16.
10
Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.发展和验证一个模型以确定 Barrett 食管进展为肿瘤的风险。
Gastroenterology. 2018 Apr;154(5):1282-1289.e2. doi: 10.1053/j.gastro.2017.12.009. Epub 2017 Dec 19.

引用本文的文献

1
Computing lifetime incidence of esophageal adenocarcinoma and age-specific prevalence of Barrett's esophagus.计算食管腺癌的终生发病率和巴雷特食管的年龄特异性患病率。
Dis Esophagus. 2025 May 3;38(3). doi: 10.1093/dote/doaf038.
2
Trends in prevalence of esophageal adenocarcinoma: Findings from a statewide database of over 6 million patients.食管腺癌患病率趋势:来自一个超过600万患者的全州数据库的研究结果。
Endosc Int Open. 2024 Feb 15;12(2):E218-E226. doi: 10.1055/a-2221-7974. eCollection 2024 Feb.
3
Effects of ranitidine and nizatidine on the risk of gastrointestinal cancer.

本文引用的文献

1
Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.巴雷特食管和食管腺癌中的生物标志物:进展和预后的预测指标。
World J Gastroenterol. 2010 Dec 7;16(45):5669-81. doi: 10.3748/wjg.v16.i45.5669.
2
Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study.巴雷特食管患者发生恶性进展的风险:一项荷兰全国性队列研究。
Gut. 2010 Aug;59(8):1030-6. doi: 10.1136/gut.2009.176701.
3
Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis.
雷尼替丁和尼扎替丁对胃肠道癌风险的影响。
Front Oncol. 2023 Jul 27;13:1182174. doi: 10.3389/fonc.2023.1182174. eCollection 2023.
4
Novel strategies for cancer immunotherapy: counter-immunoediting therapy.癌症免疫疗法的新策略:逆免疫编辑疗法。
J Hematol Oncol. 2023 Apr 13;16(1):38. doi: 10.1186/s13045-023-01430-8.
5
Lifestyle, WCRF/AICR Recommendations, and Esophageal Adenocarcinoma Risk: A Systematic Review of the Literature.生活方式、WCRF/AICR 建议与食管腺癌风险:文献系统综述。
Nutrients. 2021 Oct 8;13(10):3525. doi: 10.3390/nu13103525.
6
Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.内镜检查后食管腺癌的幅度和时间趋势分析:系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2022 Feb;20(2):e31-e50. doi: 10.1016/j.cgh.2021.04.032. Epub 2021 Apr 23.
7
Towards screening Barrett's oesophagus: current guidelines, imaging modalities and future developments.迈向巴雷特食管筛查:现行指南、成像方式及未来发展
Clin J Gastroenterol. 2020 Oct;13(5):635-649. doi: 10.1007/s12328-020-01135-2. Epub 2020 Jun 3.
8
Natural History of Barrett's Esophagus.巴雷特食管的自然史。
Dig Dis Sci. 2018 Aug;63(8):1997-2004. doi: 10.1007/s10620-018-5161-x.
9
Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.巴雷特食管恶性进展的风险分层:性别、年龄、监测持续时间和年份
World J Gastroenterol. 2016 Dec 28;22(48):10592-10600. doi: 10.3748/wjg.v22.i48.10592.
10
Potential Role of the Microbiome in Barrett's Esophagus and Esophageal Adenocarcinoma.微生物群落在巴雷特食管和食管腺癌中的潜在作用
Dig Dis Sci. 2016 Aug;61(8):2217-2225. doi: 10.1007/s10620-016-4155-9. Epub 2016 Apr 11.
巴雷特食管患者食管腺癌风险和死亡率的系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2010 Mar;8(3):235-44; quiz e32. doi: 10.1016/j.cgh.2009.10.010. Epub 2009 Oct 20.
4
Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic.巴雷特食管的非内镜筛查生物标志物:从微阵列分析到临床应用
Gut. 2009 Nov;58(11):1451-9. doi: 10.1136/gut.2009.180281. Epub 2009 Aug 2.
5
Definition of Barrett's esophagus: time for a rethink--is intestinal metaplasia dead?巴雷特食管的定义:是时候重新思考了——肠化生过时了吗?
Am J Gastroenterol. 2009 Oct;104(10):2588-94. doi: 10.1038/ajg.2009.390. Epub 2009 Jul 21.
6
Gender, hiatus hernia and Barrett's oesophagus.性别、食管裂孔疝与巴雷特食管
Gut. 2009 Jul;58(7):1025; author reply 1025-6.
7
Management of nondysplastic Barrett's esophagus: where are we now?非发育异常性巴雷特食管的管理:我们目前处于什么阶段?
Am J Gastroenterol. 2009 Apr;104(4):805-8. doi: 10.1038/ajg.2008.75.
8
Are newly diagnosed columnar-lined oesophagus patients getting younger?新诊断的柱状上皮食管患者是否越来越年轻化?
Eur J Gastroenterol Hepatol. 2009 Oct;21(10):1127-31. doi: 10.1097/MEG.0b013e328329c414.
9
The influence of symptom type and duration on the fate of the metaplastic columnar-lined Barrett's oesophagus.
Aliment Pharmacol Ther. 2009 May 15;29(10):1096-105. doi: 10.1111/j.1365-2036.2009.03969.x. Epub 2009 Feb 15.
10
Update on the diagnosis and treatment of Barrett esophagus and related neoplastic precursor lesions.巴雷特食管及相关肿瘤前体病变的诊断与治疗进展
Arch Pathol Lab Med. 2008 Oct;132(10):1577-85. doi: 10.5858/2008-132-1577-UOTDAT.